Directorate Change

Oxford Biomedica PLC
1 May 2002


                                                                                       1 May 2002

For further information, please contact:
Oxford BioMedica plc
Professor Alan Kingsman, Chief Executive                                       Tel: [phone]
City/Financial Enquiries:

Melanie Toyne Sewell / Fiona Noblet

Financial Dynamics                                                             Tel: [phone]
Scientific/Trade Press Enquiries:

Chris Gardner, HCC•De Facto Group                                              Tel: [phone]





OXFORD BIOMEDICA PLC

 CHANGES TO BOARD



Oxford, United Kingdom - 1 May 2002. Oxford BioMedica plc (LSE:OXB) ('BioMedica
') announced today that Mr. Peter Nolan is to join the Board as an executive
director as Senior Vice President for Commercial Development. In addition, Dr.
Paul Durrands has resigned from the Board of Oxford BioMedica in order to pursue
other opportunities in the biotech sector.



Peter Nolan has been a senior member of the Company since its foundation, and is
a director of the UK BioIndustry Association. Prior to joining BioMedica, he was
head of the Biotechnology Unit at the UK Department of Trade & Industry.  At
BioMedica, he has overall responsibility for the Company's patent portfolio,
which was enhanced substantially last year with several broad patents being
issued in the USA and Europe. He is also in charge of all strategic in-licensing
and technology acquisition activities. In his new role he will add to his duties
the analysis of merger and acquisition opportunities.



Commenting on the changes to the Board, the CEO of Oxford BioMedica, Professor
Alan Kingsman said:

'We are delighted to welcome Peter to the Board of Oxford BioMedica. His broad
experience in intellectual property management and technology transfer will
strengthen the Board. We wish Paul Durrands well in his new ventures and we
thank him for his contributions to the Company'.



                                     -Ends-



Notes to Editors



1.         Oxford BioMedica plc


Established in 1995, the Company specialises in the application of gene-based
technology to the development of novel therapeutics. Its three principal
activities are in the fields of gene therapy, immunotherapy and genomics, and
its principal therapeutic areas are in cancer and neurodegenerative diseases.
Oxford BioMedica plc was floated on the Alternative Investment Market of the
London Stock Exchange in December 1996, and was promoted to the United Kingdom
Listing Authority Official List in April 2001 following a successful £35.5
million fund-raising.



Oxford BioMedica is headquartered in Oxford, UK and has operating centres in
Oxford and San Diego, USA



Currently Oxford BioMedica has corporate collaborations with Aventis, IDM,
Nycomed Amersham, Valentis, Virbac and Wyeth. BioMedica has two products in
Phase I/II clinical trials: MetXia(R) for late-stage breast cancer, and TroVax
(R) for late-stage colorectal cancer.



2.       World Wide Web



This release is also available on the World Wide Web at: http://
www.oxfordbiomedica.co.uk





Addendum to Oxford BioMedica plc announcement 1 May 2002 required for RNS





Directors Disclosure



The following additional information is provided in accordance with the LSE
rules:



Current Directorships

BioIndustry Association



Past Directorships

Heart of England Training and Enterprise Council

Business Link Solutions Limited



Peter Nolan:



(i)                   does not have any unspent convictions in relation to
indictable offences;

(ii)                 has not been declared bankrupt or entered into any
individual voluntary arrangements with his creditors;

(iii)                has not been a director of any company which has been
placed in receivership, liquidation, administration, been subject to a voluntary
arrangement or any composition or arrangement with its creditors generally or
any class of its creditors whilst he was a director of that company or within
the twelve months after he ceased to be a director of that company;

(iv)                has not been a partner of any partnership at the time of or
within 12 months preceding any compulsory liquidation, administration or
partnership voluntary arrangements of such partnership;

(v)                  has not been a partner of any partnership at the time of or
within 12 months preceding a receivership of any assets of such partnership

(vi)                has not had any of his assets subject to any receivership;
and

(vii)               has not been the subject of any public criticism by
statutory or regulatory authorities or has ever been disqualified by a court
from acting as a director of a company or from acting in the management or
conduct of the affairs of any company.





                      This information is provided by RNS
            The company news service from the London Stock Exchange